Lumida
/AKBA
⌘K
Akebia Therapeutics Inc

Akebia Therapeutics Inc

AKBA
$1.34USD↓-4.29%-0.06 today

MARKET CAP

359.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$4

AI Summary

Stalk
StalkMedium

Despite the long-term downtrend, AKBA’s early Stage 1 base and the Bullish Pivot Point suggest upward mean-reversion potential. Price is currently extended above the rising short EMAs and testing resistance at the 50-day SMA without clear exhaustion, so execution should be deferred. We will await a pullback into the 9/21 EMA support zone near the base lows before initiating participation.

  • ↑Vafsio net revenues reached $15.8M in Q1, up 32% YoY.
  • ↑VOICE trial interim data shows improved safety for anemia management.
  • ↓Q1 total revenues dropped to $53.5M from $57.3M YoY.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company that focuses on developing and commercializing therapies for kidney diseases, with a particular emphasis on treating anemia related to chronic kidney disease (CKD). The company is positioned strategically within the dialysis market and has recently launched its primary product, Vafsio (vadadustat), aimed at improving patient outcomes in anemia management among dialysis patients. Given its innovative product pipeline, Akebia operates in the growing biopharmaceutical sector targeting critical unmet needs in renal healthcare.

Bull says

  • ↑Vafsio net revenues reached $15.8M in Q1, up 32% YoY.
  • ↑VOICE trial interim data shows improved safety for anemia management.
  • ↑R&D spend increased to $14.8M (from $9.8M) to advance pipeline assets.
  • ↑Partnerships with major dialysis providers expanded prescribing access.
  • ↑Cash and equivalents of $162.6M support operations for ≥2 years.
  • ↑Strong liquidity and high balance-sheet quality underpin financial stability.

Bear says

  • ↓Q1 total revenues dropped to $53.5M from $57.3M YoY.
  • ↓Negative earnings yield and weak profitability raise shareholder concerns.
  • ↓Lengthy dialysis provider adoption is slowing Vafsio uptake.
  • ↓Arixia revenues expected to decline in 2026 due to generic entry.
  • ↓High R&D expenses may strain finances if trial results lag.
  • ↓Weak momentum and negative analyst revisions point to downside risk.

Investment themes with AKBA

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • We're pleased with the progress we're seeing within and across dialysis organizations as we expand the breadth and depth of prescribing and continue to educate the nephrology community on the benefits of AFSEO.
  • We believe these data further support the potential benefits of managing anemia with VASIO and provide critical data to providers and prescribers making care decisions.
  • We expect to initiate a Phase II open-label basket trial in the second half of this year, evaluating EBRI in IgA nephropathy, lupus nephritis, and C3 glomerulopathy. These indications represent a substantial market opportunity, and of course, we're evaluating additional indications to investigate as well.

Bear points

  • Vasya will enter the dialysis bundle.
  • $53.5 million in Q126 compared to $57.3 million in Q125. This decrease was driven by lower Erixia revenues, which was partially offset by higher Vafsio revenues.
  • we expect Arixia revenues to decrease in 2026 as compared to 2025.
Read full transcript analysis ›